Phase 3 study of GALNS for the treatment of Morquio A Syndrome - ONA
Links shared publicly online about this topic.
- 535total visits
Phase 3 study of GALNS for the treatment of Morquio A Syndrome - ONA
BioMarin Pharmaceuticals announced that it has initiated a Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.
View full resource at oncologynurseadvisor.com
Tags: Disease and Condition, Pharma, Phase 3 Clinical Trial
Most Recently Shared on February 2, 2011 at 5:14 pm By:
Phase 3 study of GALNS for the treatment of Morquio A Syndrome http://goo.gl/fb/VGL7E
Phase 3 study of GALNS for the treatment of Morquio A Syndrome - MPR
empr.com — “BioMarin Pharmaceuticals announced that it has initiated a Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.” View full resource at empr.com
Most Recently Shared on February 2, 2011 at 5:45 pm By:
MPR News: Phase 3 study of GALNS for the treatment of Morquio A Syndrome: BioMarin Pharmaceuticals announced tha... http://bit.ly/ic0Z8g
Advertisement
